🔎 Trials Near Me

Hjem › Myelofibrose › Texas › Houston

Myelofibrose kliniske forsøg i Houston, TX

19 studier for Myelofibrose søger deltagere på steder i og omkring Houston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

RekruttererFase 1/2
  • MD Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04176198

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

RekruttererFase 3
  • MD Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07357727

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

RekruttererFase 1
  • The University of Texas, MD Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07469891

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

RekruttererFase 3
  • MD Anderson Cancer Center, Houston
  • The University of Utah-Huntsman Cancer Institute, Houston
  • LUMI Research, Houston
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07623161

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

RekruttererFase 1/2
  • MD Anderson, Houston
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT05320198

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

RekruttererFase 2
  • MD Anderson Cancer Center, Houston
Alder 18 til 75 · Alle køn · Opdateret 16. sep. 2026 · NCT06345495

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

RekruttererFase 1
  • University of Texas M. D. Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07441694

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

RekruttererFase 1/2
  • The University of Texas M. D. Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 15. jul. 2026 · NCT07128381

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

RekruttererFase 1
  • MD Anderson Cancer Center, Houston
Alder 13 og opefter · Alle køn · Opdateret 5. maj 2026 · NCT04771572

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

RekruttererFase 2
  • GSK Investigational Site, Houston
Alder 18 og opefter · Alle køn · Opdateret 20. apr. 2026 · NCT06517875

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

RekruttererFase 1
  • Md Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 17. apr. 2026 · NCT06034002

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

RekruttererFase 2
  • MD Anderson, Houston
Alder 18 og opefter · Alle køn · Opdateret 12. feb. 2026 · NCT05980806

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RekruttererObservationsstudie
  • Massive Bio SYNERGY-AI site, Houston
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

RekruttererFase 3
  • U.T. MD Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT06479135

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

RekruttererFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2025 · NCT05423691

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

RekruttererFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og opefter · Alle køn · Opdateret 21. feb. 2023 · NCT05280509

Myelofibrose forsøg i andre byer

Andre studier i Houston

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.